COMMUNIQUÉS West-GlobeNewswire

Algernon Health Announces Proposed Name Change to “Grey Matters Health Inc.” and a 10:1 Share Consolidation
01/04/2026
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “ Company ” or “ Algernon ”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces that it [...]
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
01/04/2026
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a [...]
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
31/03/2026
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a [...]
Axe Compute Inc. Reports Full-Year 2025 Financial Results
31/03/2026
Completed Strategic Transformation to AI Compute Infrastructure Raised $343.5 Million in Capital to Fund Digital Asset Treasury Strategy Solidified new leadership composition with world class CEO and board members [...]
Cognition Therapeutics CEO Issues Letter to Shareholders
31/03/2026
Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, [...]
BioAtla Announces Share Consolidation
31/03/2026
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody [...]
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2025
31/03/2026
Le programme de développement global de JNJ-1900 (NBTXR3) a progressé comme prévu, ouvrant la voie à une opportunité d’adresser l’un des plus grands marchés encore inexploités en oncologie grâce aux programmes les plus [...]
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
31/03/2026
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high- [...]
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
31/03/2026
ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million; Cyprium [...]
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
31/03/2026
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous [...]
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
31/03/2026
HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
31/03/2026
Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer [...]
NeuroSalt Claims Evaluated: What the Pink Salt Trick Research Says About Neuro Salt Supplementation for Nerve Health
31/03/2026
An informational overview of NeuroSalt ingredients, pink salt trick marketing claims, nerve pain supplement research context, pricing, refund policy, and what to know before buying Neuro Salt in 2026 Lakeland, FL, March [...]
Milestone Scientific Reports Financial Results for Fourth Quarter and Full Year 2025
31/03/2026
Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE [...]
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
31/03/2026
MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to [...]
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
31/03/2026
Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: [...]
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
31/03/2026
Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Significant Revenue [...]
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
31/03/2026
Company outlines near-term pharmacokinetic milestones, highlights amorphous formulation strategy, and announces planned global patent filing TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ( [...]
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
31/03/2026
Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative [...]

Pages